Navigation Links
Genzyme and Bayer Schering Pharma AG, Germany Announce Start of Phase 3 Program with Alemtuzumab for Treatment of Multiple Sclerosis
Date:9/26/2007

cation in 2001 in the US, where it is marketed by Bayer HealthCare Pharmaceuticals Inc. as Campath(R), and in Europe, where it is named MabCampath(R).

Alemtuzumab is a humanized monoclonal antibody that binds to a specific target, CD52, on cell surfaces and directs the body's immune system to destroy those cells. It is the first and only monoclonal antibody approved by the FDA for the treatment of patients with B-CLL.

Genzyme and Bayer Schering Pharma AG, Germany are co-developing alemtuzumab in oncology, multiple sclerosis and other indications. Bayer Schering Pharma AG, Germany holds exclusive worldwide marketing and distribution rights to alemtuzumab.

Campath has a boxed warning which includes information on cytopenias, infusion reactions, and infections. The most commonly reported adverse reactions in patients with B-CLL were infusion reactions (fever, chills, hypotension, urticaria, nausea, rash, tachycardia, dyspnea), cytopenias (neutropenia, lymphopenia, thrombocytopenia, anemia), and infections (CMV viremia, CMV infection, other infections). In clinical trials, the frequency of infusion reactions was highest in the first week of treatment. Other commonly reported adverse reactions include vomiting, abdominal pain, insomnia and anxiety. The most commonly reported serious adverse reactions are cytopenias, infusion reactions, and immunosuppression/infections.

About Genzyme

One of the world's leading biotechnology companies, Genzyme is dedicated to making a major positive impact on the lives of people with serious diseases. Since 1981, the company has grown from a small start-up to a diversified enterprise with more than 9,500 employees in locations spanning the globe and 2006 revenues of $3.2 billion. In 2007, Genzyme was chosen to receive the National Medal of Technology, the highest honor awarded by the President of the United States for technological innovation. In 2006 and 2007, Genzyme was selected by FORTUNE as one of the "10
'/>"/>

SOURCE Genzyme Corporation; Bayer Schering Pharma AG
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
2. Genzyme Announces Results of Clinical Trial of Hylastan
3. Genzyme Announces Results of Clinical Trials Investigating Powder Form of Sevelamer Carbonate
4. Genzyme Announces Results of Clinical Trials Investigating Powder Form of Sevelamer Carbonate
5. Genzyme and Bayer HealthCare Announce Detailed Interim Two-Year Alemtuzumab in Multiple Sclerosis Data Presented at AAN
6. Genzyme Announces Successful Completion of Study Investigating Sevelamer Carbonate in Patients With Chronic Kidney Disease
7. Schering-Plough Announces Hepatitis C Data Presentations at Digestive Disease Week (DDW) 2007 Annual Meeting
8. Schering-Plough Addresses Major Milestones and Challenges in Treatment of Patients With Chronic Hepatitis C
9. Schering-Plough Announces Presentation of Phase II Trial Results for Novel Oral Thrombin Receptor Antagonist at the 2007 Annual Meeting of The American College of Cardiology/i2 Summit
10. Sygnis Pharma AG announces date for presentation of clinical results
11. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... , July 31, 2015  Physicians and payers ... the biopharmaceutical market. Patients are better informed and ... and switching therapies. This shift in power is ... efforts toward patient-focused marketing. As part ... have learned it,s important to educate, communicate and ...
(Date:7/31/2015)... -- Seeger Weiss LLP is reporting that on July 13, 2015, ... C.R. Bard, the manufacturer of Inferior vena cava (IVC) ... the agency found at two of Bard,s facilities. Bard was ... them during Inspectional Observations that occurred on November 18, 2014, ... , location and on October 6, 2014, through November ...
(Date:7/31/2015)... 2015 Today, the National Association of ... issued a report urging greater accountability by the ... against websites illegally selling medications online. As detailed ... Program Progress Report for State and Federal Regulators: ... websites illegally distribute medications and avoid retribution. Such ...
Breaking Medicine Technology:Consumers Forcing Pharmaceutical Industry to Shift its Marketing Focus from Products to Patients 2Seeger Weiss LLP Reports That The FDA Has Issued A Warning Letter To IVC Filter Manufacturer, C.R. Bard 2Seeger Weiss LLP Reports That The FDA Has Issued A Warning Letter To IVC Filter Manufacturer, C.R. Bard 3NABP Stresses Need for Accountability in Enforcing Internet Policies to Protect the Public From Illegal Online Drug Sellers 2NABP Stresses Need for Accountability in Enforcing Internet Policies to Protect the Public From Illegal Online Drug Sellers 3
... June 8, 2011 ForteBio®, Inc., a leading ... of biotherapeutic and pharmaceutical products, today announced the ... Fc Capture (AMC) biosensor for use on the ... high-throughput rapid kinetic characterization and screening of mouse ...
... 8, 2011 TetraLogic Pharmaceuticals, a biopharmaceutical company developing ... today announced the appointment of Mr. Jonathan B. Lloyd ... president of corporate development. Mr. Lloyd ... development and finance experience.  He has led negotiations, valuation ...
Cached Medicine Technology:ForteBio Introduces New Biosensor for Kinetic Analysis and Screening of Mouse IgG Antibodies 2TetraLogic Appoints Jonathan B. Lloyd Jones as Chief Financial Officer and Vice President Corporate Development 2
(Date:8/3/2015)... ... 2015 , ... Novatus, Inc. today launched the largest and ... as announced the date of its next major release. , Version 6.0 introduces ... as well as enhancements to the customer experience. Users now enjoy a ...
(Date:8/3/2015)... ... 03, 2015 , ... Results of a comprehensive survey by ... and Policy Analysis show widespread support for the U.S. Affordable Care Act among ... agreed that the controversial law passed in 2010 had “more good than bad” ...
(Date:8/3/2015)... ... August 03, 2015 , ... Sensato and ... Secure Healthcare Systems” This three-day, highly interactive and immersive workshop, has been ... access to the tactics, techniques and practices required to design and develop highly ...
(Date:8/3/2015)... ... August 03, 2015 , ... The U.S. Food and Drug Administration (FDA) ... similar to deoxycholic acid, which occurs naturally in the body and helps absorb and ... this area of the body. These are invasive procedures and very expensive for most ...
(Date:8/3/2015)... ... ... A July 13 article from The Daily Mail titled "Jab That ... Can Last 'For Five Weeks'" discusses the use of stem cells to help ... harvesting stem cell-rich bone marrow from the hip, known as bone marrow stromal cells ...
Breaking Medicine News(10 mins):Health News:Novatus Unveils Milestone Software Release 2Health News:Survey Finds Support for the Affordable Care Act Among Physician Leaders 2Health News:Survey Finds Support for the Affordable Care Act Among Physician Leaders 3Health News:Sensato and Divurgent are pleased to announce the development of it’s new program “Designing Secure Healthcare Systems” 2Health News:Sensato and Divurgent are pleased to announce the development of it’s new program “Designing Secure Healthcare Systems” 3Health News:Sensato and Divurgent are pleased to announce the development of it’s new program “Designing Secure Healthcare Systems” 4Health News:Dr. Ava Shamban to Offer the New Double Chin Treatment Kybella 2Health News:Dr. Ava Shamban to Offer the New Double Chin Treatment Kybella 3Health News:Los Angeles Spine Surgeon Gives Insight into How Stem Cells Can Relieve Back Pain 2Health News:Los Angeles Spine Surgeon Gives Insight into How Stem Cells Can Relieve Back Pain 3
... , To The Editor: Recent deaths ... bacterial,infections in shellfish should remind people with certain ... shellfish,particularly during warm weather when waters in the ... of Vibrio vulnificus bacteria., Vibrio vulnificus is ...
... 15 Young Innovations, Inc.,(Nasdaq: YDNT ) today ... with a live and on-demand web cast conference call ... live audio broadcast of the,call will be available through ... broadcast will also be available through the,Company,s website, ...
... PARK, Calif., Oct. 15 Exponent, Inc.,(Nasdaq: EXPO ... ended,September 26, 2008., For the third quarter of ... $48,904,000, in the same period of 2007.,Revenues before reimbursements ... Net income was up 18% to $5,942,000, or $0.38 ...
... Hospice Pediatric Patients, WASHINGTON, Oct. 15 ... (USAID) and funding from the U.S.,President,s Emergency Plan ... has developed one of South Africa,s first children,s ... by youngsters with,life-threatening illnesses, including AIDS and cancer., ...
... University and Delta Dental Foundation project is working to ... of thousands of Indiana children, INDIANAPOLIS, Oct. 15 ... between January and September 2008 by an,Indiana University School of ... Indiana, a mobile dental sealant program operated by the,university and ...
... mathematician who has applied mathematical modeling techniques to elucidate the ... methods to ascertain the players most deserving of major league ... awards. Bukiet, a popular NJIT math professor, dives annually ... game, but also for his love of teaching and math. ...
Cached Medicine News:Health News:Important Health Issue From Be Oyster Aware 2Health News:Young Innovations, Inc. Provides Third Quarter Conference Call Details 2Health News:Exponent Reports Third Quarter 2008 Results 2Health News:Exponent Reports Third Quarter 2008 Results 3Health News:Exponent Reports Third Quarter 2008 Results 4Health News:Exponent Reports Third Quarter 2008 Results 5Health News:Exponent Reports Third Quarter 2008 Results 6Health News:Exponent Reports Third Quarter 2008 Results 7Health News:Exponent Reports Third Quarter 2008 Results 8Health News:Children with Life-Threatening Illnesses Receive Hospice Care 2Health News:SEAL Indiana Reports More Than Half of Indianapolis Area School Kids Treated by Program Have Moderate or Severe Dental Decay 2Health News:Using math model, NJIT professor names MVP and Cy Young award contenders 2Health News:Using math model, NJIT professor names MVP and Cy Young award contenders 3
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: